Ceritinib outperforms chemotherapy as firstline treatment for advanced ALK+ NSCLC in latest Phase III datahttps://t.co/7TqoGIpYpN

Ceritinib outperforms chemotherapy as firstline treatment for advanced ALK+ NSCLC in latest Phase III data https://t.co/7TqoGIpYpN

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/826469286491410432
via IFTTT